ExpressionEdits has secured $13M in seed funding to enhance protein expression using AI-driven intronization technology. This innovative approach optimizes genetic design by integrating introns, crucial for effective gene expression. CEO and co-founder Dr. Kärt Tomberg developed this method during the COVID-19 pandemic, revolutionizing the production of challenging proteins. The company's Genetic Syntax Engine perfects genetic grammar, enabling the creation of high-value therapeutic proteins. ExpressionEdits seeks partnerships to advance gene therapy optimization. Key team members include Dr. Rebecca Godfrey (COO), Dr. Leopold Parts (CTO), and advisors like Prof. Allan Bradley.